Abstract
BackgroundPegloticase (PGL) is FDA-approved for refractory chronic gout. Two previous replicate Phase 3 clinical trials were conducted to assess the efficacy and safety of PGL therapy (1). Chronic kidney disease...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
